English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

RNA targeting the murine vascular endothelial growth factor receptor 2 (VEGFR2)gene was designed and validated for efficient and robust silencing in vitro andwas delivered by polyethylenimines (PEI) in vivo to investigate the antitumoreffect on non-small cell lung cancer (NSCLC) xenografts. The following dosageregimens were tested for their tumor inhibitory effect in vivo: VEGFR2 siRNA,epidermal growth factor receptor (EGFR) siRNA, VEGFR2 siRNA+EGFR siRNA, cisplatinalone and VEGFR2 siRNA+ EGFR siRNA+cisplatin. Targeted silencing of both VEGFR2and EGFR expression by siRNA, combined with low-dose cisplatin, was found to effectivelyinhibit tumor growth and extend the survival time of mice bearing the NSCLC xenografts.These results suggest that combination therapy using siRNAs and chemotherapy agentsmight offer a novel strategy for cancer treatment in the future.

Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts